Drug profile

The FDA adverse-event record for Omega-3

115 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Omega-3. See the species affected, top reactions, and outcomes below.

115
adverse-event reports
9.6%
death-coded share
Dog
most-reported species
15
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
115
Total Reports
11
Deaths Reported
9.6%
Death Rate

Active Ingredients

Omega-3

Administration Routes

UnknownOral

Species Affected

Dog 112
Cat 3

Most Affected Breeds

Retriever - Labrador 16
Shepherd Dog - German 5
Retriever - Golden 5
Terrier - Yorkshire 5
Schnauzer - Miniature 4
Boxer (German Boxer) 4
Shih Tzu 3
Dachshund - Miniature 3
Shepherd Dog - Australian 3
Terrier (unspecified) 3

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 15
Lack of efficacy - NOS 13
Vomiting 12
INEFFECTIVE, LOSS OF EFFECT 12
Diarrhoea 11
INEFFECTIVE, ATOPY CONTROL 11
Anorexia 10
Elevated alanine aminotransferase (ALT) 10
Behavioural disorder NOS 9
Elevated serum alkaline phosphatase (SAP) 7
Elevated creatinine 7
Other abnormal test result NOS 7

Outcome Breakdown

Ongoing
68 (59.1%)
Outcome Unknown
22 (19.1%)
Recovered/Normal
14 (12.2%)
Euthanized
6 (5.2%)
Died
5 (4.3%)

Omega-3 Adverse Event Insights

115 reports name Omega-3; 11 recorded a death outcome (9.6% of reported events, not a population-level mortality rate). Active ingredient: Omega-3. Administration routes: Unknown, Oral.

By species: Dog (112 reports), Cat (3 reports). By breed: Retriever - Labrador (16), Shepherd Dog - German (5), Retriever - Golden (5).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (15), Lack of efficacy - NOS (13), Vomiting (12), INEFFECTIVE, LOSS OF EFFECT (12). Outcome, 115 coded reports: Ongoing leads at 59.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.